To assess the selectivity and the kinase inhibition profile of the most active dual inhibitor of this new series (9f), an in vitro screening assay was performed over a small panel of cancer-related kinases including fibroblast growth factor receptor 1 (FGFR1), vascular endothelial growth factor receptor 2 (VEGFR2), cyclin-dependent kinase 2 (CDK2), c-mesenchymal-epithelial transition factor (c-MET), and p38α mitogen-activated protein kinase (MAPK14) in a single-dose concentration of 10 μM. The gene discussed is CDK2; the disease is cancer.